Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

85.75USD
26 Jun 2017
Change (% chg)

$-0.59 (-0.68%)
Prev Close
$86.34
Open
$85.79
Day's High
$86.20
Day's Low
$85.73
Volume
321,719
Avg. Vol
495,358
52-wk High
$86.90
52-wk Low
$66.93

NVS.N

Chart for NVS.N

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $225,385.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.72
Yield (%): 3.15

Financials

  NVS.N Industry Sector
P/E (TTM): 32.50 14.09 19.01
EPS (TTM): 2.66 -- --
ROI: 6.05 -6.73 -5.03
ROE: 9.13 -6.18 -4.28

Swiss stocks - Factors to watch on June 27

ZURICH, June 27 Here are some of the main factors that may affect Swiss stocks on Tuesday:

1:34am EDT

Novartis gets European OK for biosimilar of Amgen's Enbrel

ZURICH, June 27 Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.

1:31am EDT

Germany's Merck gets EU backing for oral MS drug

(This June 23 story corrects second paragraph to show that the recommendation is to approve the relapsing forms, not the relapsing-remitting form of MS.)

Jun 24 2017

CORRECTED-Germany's Merck gets EU backing for oral MS drug

FRANKFURT, June 23 Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral multiple sclerosis (MS) drugs in Europe, six years after its first attempt to launch the cladribine pill failed.

Jun 24 2017

Novartis breast cancer drug Kisqali wins European panel backing

ZURICH A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.

Jun 23 2017

UPDATE 1-Novartis breast cancer drug Kisqali wins European panel backing

ZURICH, June 23 A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.

Jun 23 2017

Novartis breast cancer drug Kisqali wins European panel nod

ZURICH, June 23 A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.

Jun 23 2017

BRIEF-Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic NSCLC

* Novartis combination targeted therapy tafinlar + mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)

Jun 22 2017

BRIEF-Regeneron details royalty agreement with Novartis for canakinumab

* Regeneron details royalty agreement with novartis for canakinumab (acz885)

Jun 22 2017

Novartis heart drug success opens up new care option

ZURICH/LONDON A Novartis anti-inflammatory drug cut cardiovascular risk for heart attack survivors in a pivotal trial, potentially changing ideas about treatment.

Jun 22 2017

More From Around the Web

Competitors

Earnings vs. Estimates